Alzheimer's disease
Eisai, Biogenās Leqembi reduces amyloid in Alzheimerās, but safety concerns remain
Amid mounting concerns regarding the potential strain on healthcare infrastructure due to Leqembi, a drug for Alzheimer’s disease, Eisai and ...
Araclonās Alzheimerās vaccine shows promise in phase 2 trial
Araclon Biotech, a subsidiary of Grifols, has unveiled promising early evidence regarding the effectiveness of its Alzheimer’s disease vaccine. In ...
CMS proposes to cover more PET scans for Alzheimerās disease diagnosis
This year, promising drug treatments for Alzheimer’s disease have emerged, prompting the Centers for Medicare and Medicaid Services (CMS) to ...
Roche and Ionis expand partnership with new RNA programs for Alzheimerās and Huntingtonās
Roche, in its quest to find effective treatments for Alzheimer’s diseases after the setbacks of gantenerumab, has reaffirmed its commitment ...
First Wave acquires Sanofiās Alzheimerās drug for GI disorders, retains buyback option
First Wave BioPharma has seized an opportunity from Sanofi to revive a long-dormant molecule, capeserod, by paying an upfront sum ...
Ad Council and Alzheimer’s Association’s Fresh Push to Raise Alzheimer’s Awareness in Hispanic Community
The Ad Council and the Alzheimer’s Association (AA) have unveiled a poignant new slogan, “Some Things Come with Age,” designed ...
Some individuals’ cognitive deterioration may be slowed by hearing aids
Amid the focus on expensive therapies targeting amyloid for Alzheimer’s disease, a new clinical study highlights an alternative approach to ...
Eisai Unveils Lecanemab’s Alzheimer’s Breakthrough at AAIC 2023
Source – Eisai July 20, 2023 Biogen revealed the results of a comprehensive analysis of the Phase III Clarity AD ...
Donanemab Shows Significant Advance in Alzheimerās Treatment
Source – Eli Lilly The full data from Eli Lilly’s TRAILBLAZER-ALZ 2 trial of the amyloid drug donanemab has validated ...
How will Medicare be affected by the cost of Leqembi from Eisai and Biogen? Sen. Sanders is curious
Senator Bernie Sanders (I-Vt.) is increasing his pressure on the US Department of Health and Human Services (HHS) regarding the ...
BMS purchases the Prothena Alzheimer’s medication in a $2.2 billion transaction
Source: Prothena Bristol-Myers Squibb has taken an option on a tau protein-targeting antibody in early-stage clinical development from Prothena on ...
Eisai has requested to approve Leqembi, its therapy for Alzheimer’s disease, in South Korea
This filing comes just before an FDA advisory committee meeting, which has raised expectations of the drug receiving full approval ...
